8-K
Galera Therapeutics, Inc. (GRTX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 24, 2025
GALERA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39114 | 46-1454898 |
|---|---|---|
| (State or other jurisdiction of<br><br>incorporation or organization) | (Commission<br><br>File Number) | (I.R.S. Employer<br><br>Identification No.) |
101 Lindenwood Drive, Suite 225
Malvern, PA 19355
(Address of principal executive offices) (Zip Code)
(610) 725-1500
(Registrant’s telephone number, include area code)
45 Liberty Blvd #230
Malvern, PA 19355
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br>Symbol(s) | Name of each exchange<br><br>on which registered |
|---|---|---|
| Common Stock, $0.001 par value per share | GRTX | OTC Pink Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
|---|
At the 2024 annual meeting of stockholders (the “Annual Meeting”) of Galera Therapeutics, Inc. (the “Company”) held on February 24, 2025, the Company’s stockholders (i) elected two Class II directors to the board of directors of the Company, each to serve a three-year term until the Company’s 2027 annual meeting of stockholders and until their successors are duly elected and qualified; and (ii) ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2024.
The results of the voting at the Annual Meeting are shown below:
Proposal 1—Election of Class II Directors:
| Nominee | For | Withhold | Broker Non-Votes | ||
|---|---|---|---|---|---|
| Lawrence Alleva | 27,501,778 | 3,359,405 | 10,682,973 | ||
| Kevin Lokay | 27,504,038 | 3,357,145 | 10,682,973 |
Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm:
| Votes For | Votes Against | Abstentions |
|---|---|---|
| 41,342,291 | 184,580 | 17,285 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GALERA THERAPEUTICS, INC. | ||
|---|---|---|
| Date: February 25, 2025 | By: | /s/ J. Mel Sorensen, M.D. |
| J. Mel Sorensen, M.D. | ||
| President and Chief Executive Officer |